IP Library Granted Patent US 8,410,272
Granted Patent B2
US 8,410,272 · App. 12/910,744 · Granted Apr 2, 2013

Pyrazolylbenzothiazole derivatives and their use as therapeutic agents

Inventors: Zaihui Zhang (Vancouver, CA); Timothy S Daynard (Vancouver, CA); Shisen Wang (Coquitlam, CA); Xinyao Du (Richmond, CA); Gregory B Chopiuk (San Diego, CA); Jun Yan (Coquitlam, CA); Jianxin Chen (Vancouver, CA); Serguei V Sviridov (Burnaby, CA)
Assignee: Dermira (Canada), Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,410,272
App. No.
12/910,744
Granted
Apr 2, 2013
Kind
B2
Abstract

Pharmaceutical compositions and compounds are provided. The compounds of the invention have use as therapeutic agents, e.g., they demonstrate anti-proliferative, anti-inflammatory, anti-angiogenic, anti-migration activities. In one embodiment of the invention, formulations of the compounds in combination with a physiologically acceptable carrier are provided. The pharmaceutical formulations are useful in the treatment of, e.g., anti-inflammatory, renal, and hyperproliferative disorders. The compounds of the invention are pyrazolylbenzothiazole derivatives of the following formula (1) wherein X, R 1 , R 2 , R 3 and R 4 are described herein.

Claims (34)

1. A pharmaceutical composition comprising a pharmaceutically acceptable excipient and a compound of formula (3):

as a single tautomer, a mixture of tautomers, a single stereoisomer, a mixture of stereoisomers, or a racemic mixture; or a pharmaceutically acceptable salt thereof; wherein:

R 2 at each occurrence is independently selected from aminosulfinyl, aminosulfonyl, aryl, azido, halogen, heteroalkyl, heteroaryl, hydrazinyl, hydrocarbyl, hydrogen, hydroxyl, nitro, nitroso, phosphate, phosphinate, phosphonate, phosphonium, phosphorothioate, phosphoryl, sulfamoyl, sulfate, sulfinic acid, sulfonamido, sulfonate, sulfonic acid, sulfoxido, thiol, thioureido, and ureido;

R 3 at each occurrence is independently selected from amino, aminosulfinyl, aminosulfonyl, aryl, azido, halogen, heteroalkyl, heteroaryl, hydrazinyl, hydrocarbyl, hydrogen, hydroxyl, nitro, nitroso, phosphate, phosphinate, phosphonate, phosphonium, phosphorothioate, phosphoryl, sulfamoyl, sulfate, sulfinic acid, sulfonamido, sulfonate, sulfonic acid, sulfoxido, thiol, thioureido, and ureido;

R 4 is selected from hydrogen, heteroalkyl, heteroaryl, and hydrocarbyl;

X is S; and

Y is a 6 membered heterocycle having 1 or 2 nitrogen atoms and which is optionally further substituted by one or more groups selected from amino, aminosulfinyl, aminosulfonyl, aryl, azido, halogen, heteroalkyl, heteroaryl, hydrazinyl, hydrocarbyl, hydrogen, hydroxyl, nitro, nitroso, phosphate, phosphinate, phosphonate, phosphonium, phosphorothioate, phosphoryl, sulfamoyl, sulfate, sulfinic acid, sulfonamido, sulfonate, sulfonic acid, sulfoxido, thiol, thioureido, and ureido.

2. A composition according to claim 1 wherein heteroalkyl is selected from aminohydrocarboyl (i.e., —NH—C(═O)-Hy), amido (i.e., —C(═O)—NH 2 ), carboxylic acid (i.e., —COOH), cyano (i.e., —CN), dihydrocarbylamido (i.e., —C(═O)—N(Hy)(Hy)), dihydrocarbylamino (i.e., —N(Hy)(Hy)), di(hydrocarbyl)phosphido, formyl (i.e., —C(═O)H), hydrocarboyl (i.e., —C(═O)-Hy), hydrocarboyloxy (i.e., —O—C(═O)-Hy) hydrocarbylamino (i.e., —NH-Hy), hydrocarbyloxy (i.e., —O-Hy), hydrocarbyloxycarbonyl (i.e., —C(═O)—O-Hy) hydrocarbylsiloxy, hydrocarbylsilylamino, hydrocarbylsulfido (i.e., —S-Hy), hydrocarbylthio, hydrocarbylamido (i.e., —C(═O)—N(H)(Hy)), isothiocyanate, N-heterocycle, perfluorohydrcarbyl, thiocyanate, and hydrocarbyl substituted with one or more groups selected from alkylamino, amino, aminosulfinyl, aminosulfonyl, azido, dialkylamino, halogen, heteroalkyl, heteroaryl, hydrazinyl, hydroxyl, nitro, nitroso, phosphate, phosphinate, phosphonate, phosphonium, phosphorothioate, phosphoryl, sulfamoyl, sulfate, sulfinic acid, sulfonamido, sulfonate, sulfonic acid, sulfoxido, thiol, thioureido, and ureido.

3. The composition of claim 1 where hydrocarbyl is selected from the group consisting of alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylene, and aryl, wherein:

alkyl, alkenyl and alkynyl is optionally substituted with one or more Hy 1 groups selected from cycloalkyl, cycloalkylene and aryl, where each Hy 1 group is optionally substituted with one or more Hy 2 groups selected from alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylene, and aryl; and

cycloalkyl, cycloalkylene and aryl is optionally substituted with one or more Hy 2 groups;

provided that when Hy 2 is selected from alkyl, alkenyl or alkynyl, then Hy 2 may be substituted with one or more Hy 3 groups selected from cycloalkyl, cycloalkylene and aryl, where each Hy 3 group is optionally substituted with one or more Hy 4 groups selected from alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylene, and aryl, and when Hy 2 is selected from cycloalkyl, cycloalkylene and aryl then Hy 2 is optionally substituted with one or more Hy 4 groups; and

further provided that aryl includes an aryl ring fused to a non-aromatic hydrocarbocyclic ring.

4. The composition of claim 1 wherein R 4 is hydrogen.

5. The composition of claim 1 wherein R 2 is selected from lower alkyl and lower haloalkyl.

6. The composition of claim 1 wherein R 3 is amino.

7. The composition of claim 1 wherein the compound of formula (3) is 5-methyl-4-thiazolo[5,4-b]pyridin-2-yl-1H-pyrazazol-3-ylamine.

8. A compound of formula (3):

as a single tautomer, a mixture of tautomers, a single stereoisomer, a mixture of stereoisomers, or a racemic mixture; or a pharmaceutically acceptable salt thereof; wherein:

R 2 at each occurrence is independently selected from aminosulfinyl, aminosulfonyl, aryl, azido, halogen, heteroalkyl, heteroaryl, hydrazinyl, hydrocarbyl, hydrogen, hydroxyl, nitro, nitroso, phosphate, phosphinate, phosphonate, phosphonium, phosphorothioate, phosphoryl, sulfamoyl, sulfate, sulfinic acid, sulfonamido, sulfonate, sulfonic acid, sulfoxido, thiol, thioureido, and ureido;

R 3 at each occurrence is independently selected from amino, aminosulfinyl, aminosulfonyl, aryl, azido, halogen, heteroalkyl, heteroaryl, hydrazinyl, hydrocarbyl, hydrogen, hydroxyl, nitro, nitroso, phosphate, phosphinate, phosphonate, phosphonium, phosphorothioate, phosphoryl, sulfamoyl, sulfate, sulfinic acid, sulfonamido, sulfonate, sulfonic acid, sulfoxido, thiol, thioureido, and ureido;

R 4 is selected from hydrogen, heteroalkyl, heteroaryl, and hydrocarbyl;

X is S; and

Y is a 6 membered heterocycle having 1 or 2 nitrogen atoms and which is optionally further substituted by one or more groups selected from amino, aminosulfinyl, aminosulfonyl, aryl, azido, halogen, heteroalkyl, heteroaryl, hydrazinyl, hydrocarbyl, hydrogen, hydroxyl, nitro, nitroso, phosphate, phosphinate, phosphonate, phosphonium, phosphorothioate, phosphoryl, sulfamoyl, sulfate, sulfinic acid, sulfonamido, sulfonate, sulfonic acid, sulfoxido, thiol, thioureido, and ureido.

9. The compound of claim 8 wherein heteroalkyl is selected from aminohydrocarboyl (i.e., —NH—C(═O)-Hy), amido (i.e., —C(═O)—NH 2 ), carboxylic acid (i.e., —COOH), cyano (i.e., —CN), dihydrocarbylamido (i.e., —C(═O)—N(Hy)(Hy)), dihydrocarbylamino (i.e., —N(Hy)(Hy)), di(hydrocarbyl)phosphido, formyl (i.e., —C(═O)H), hydrocarboyl (i.e., —C(═O)-Hy), hydrocarboyloxy (i.e., —O—C(═O)-Hy) hydrocarbylamino (i.e., —NH-Hy), hydrocarbyloxy (i.e., —O-Hy), hydrocarbyloxycarbonyl (i.e., —C(═O)—O-Hy) hydrocarbylsiloxy, hydrocarbylsilylamino, hydrocarbylsulfido (i.e., —S-Hy), hydrocarbylthio, hydrocarbylamido (i.e., —C(═O)—N(H)(Hy)), isothiocyanate, N-heterocycle, perfluorohydrcarbyl, thiocyanate, and hydrocarbyl substituted with one or more groups selected from alkylamino, amino, aminosulfinyl, aminosulfonyl, azido, dialkylamino, halogen, heteroalkyl, heteroaryl, hydrazinyl, hydroxyl, nitro, nitroso, phosphate, phosphinate, phosphonate, phosphonium, phosphorothioate, phosphoryl, sulfamoyl, sulfate, sulfinic acid, sulfonamido, sulfonate, sulfonic acid, sulfoxido, thiol, thioureido, and ureido.

10. The compound of claim 8 where hydrocarbyl is selected from the group consisting of alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylene, and aryl, wherein:

alkyl, alkenyl and alkynyl is optionally substituted with one or more Hy 1 groups selected from cycloalkyl, cycloalkylene and aryl, where each Hy 1 group is optionally substituted with one or more Hy 2 groups selected from alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylene, and aryl; and

cycloalkyl, cycloalkylene and aryl is optionally substituted with one or more Hy 2 groups;

provided that when Hy 2 is selected from alkyl, alkenyl or alkynyl, then Hy 2 may be substituted with one or more Hy 3 groups selected from cycloalkyl, cycloalkylene and aryl, where each Hy 3 group is optionally substituted with one or more Hy 4 groups selected from alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylene, and aryl, and when Hy 2 is selected from cycloalkyl, cycloalkylene and aryl then Hy 2 is optionally substituted with one or more Hy 4 groups; and

further provided that aryl includes an aryl ring fused to a non-aromatic hydrocarbocyclic ring.

11. The compound of claim 8 wherein R 4 is hydrogen.

12. The compound of claim 8 wherein R 2 is selected from lower alkyl and lower haloalkyl.

13. The compound of claim 8 wherein R 3 is amino.

14. The composition of claim 8 being 5-methyl-4-thiazolo[5,4-b]pyridin-2-yl-1H-pyrazazol-3-ylamine.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 18, 2014
From: QLT INC.
To: VALOCOR THERAPEUTICS, INC.
Reel/Frame 033133/0246 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 18, 2014
From: ZHANG, ZAIHUI; DAYNARD, TIMOTHY S.; WANG, SHISEN; DU, XINYAO; CHOPIUK, GREGORY B.; YAN, JUN; CHEN, JIANXIN; SVIRIDOV, SERGUEI V.
To: QLT INC.
Reel/Frame 033133/0253 →
CHANGE OF NAME Recorded Jan 26, 2012
From: VALOCOR THERAPEUTICS
To: DERMIRA (CANADA), INC.
Reel/Frame 027602/0401 →
Continuity (2)
Continuation 10521948
Related Publication 20110178126A1 · Jul 21, 2011